In cystic fibrosis (CF), the deletion of phenylalanine 508 (F508del) in the CF transmembrane conductance regulator (CFTR) leads to misfolding and premature degradation of the mutant protein. These defects can be targeted with pharmacological agents named potentiators and correctors. During the past years, several efforts have been devoted to develop and approve new effective molecules. However, their clinical use remains limited, as they fail to fully restore F508del-CFTR biological function. Indeed, the search for CFTR correctors with different and additive mechanisms has recently increased. Among them, drugs that modulate the CFTR proteostasis environment are particularly attractive to enhance therapy effectiveness further. This Perspective focuses on reviewing the recent progress in discovering CFTR proteostasis regulators, mainly describing the design, chemical structure, and structure-activity relationships. The opportunities, challenges, and future directions in this emerging and promising field of research are discussed, as well.

Brusa I., Sondo E., Falchi F., Pedemonte N., Roberti M., Cavalli A. (2022). Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives. JOURNAL OF MEDICINAL CHEMISTRY, 65(7), 5212-5243 [10.1021/acs.jmedchem.1c01897].

Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives

Brusa I.;Falchi F.;Roberti M.
;
Cavalli A.
2022

Abstract

In cystic fibrosis (CF), the deletion of phenylalanine 508 (F508del) in the CF transmembrane conductance regulator (CFTR) leads to misfolding and premature degradation of the mutant protein. These defects can be targeted with pharmacological agents named potentiators and correctors. During the past years, several efforts have been devoted to develop and approve new effective molecules. However, their clinical use remains limited, as they fail to fully restore F508del-CFTR biological function. Indeed, the search for CFTR correctors with different and additive mechanisms has recently increased. Among them, drugs that modulate the CFTR proteostasis environment are particularly attractive to enhance therapy effectiveness further. This Perspective focuses on reviewing the recent progress in discovering CFTR proteostasis regulators, mainly describing the design, chemical structure, and structure-activity relationships. The opportunities, challenges, and future directions in this emerging and promising field of research are discussed, as well.
2022
Brusa I., Sondo E., Falchi F., Pedemonte N., Roberti M., Cavalli A. (2022). Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives. JOURNAL OF MEDICINAL CHEMISTRY, 65(7), 5212-5243 [10.1021/acs.jmedchem.1c01897].
Brusa I.; Sondo E.; Falchi F.; Pedemonte N.; Roberti M.; Cavalli A.
File in questo prodotto:
File Dimensione Formato  
acs.jmedchem.1c01897.pdf

accesso aperto

Descrizione: Perspective
Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 9.35 MB
Formato Adobe PDF
9.35 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/884305
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 10
  • ???jsp.display-item.citation.isi??? ND
social impact